← Back

Wire · opportunities

Rezatapopt Pill Shrank Tumors in 48% of Women With Platinum-Resistant Ovarian Cancer

Published

21 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medicaldaily.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

An experimental pill called rezatapopt showed tumor shrinkage in 48% of women with platinum-resistant ovarian cancer carrying the TP53 Y220C mutation, based on a Phase 2 trial. PMV Pharmaceuticals plans to seek accelerated FDA approval in early 2027, though the trial lacked a control group and did not demonstrate improved survival.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

The FDA fast-track path opens an early window for companies developing targeted ovarian cancer treatments that exploit rare mutations. You must now prioritise genetic testing partnerships to identify eligible patients swiftly and gain early market access.

◆ Coverage

1 source · 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechovarian-cancerpharma-approvaltp53-mutationclinical-trialoncology